OncoMatch/Clinical Trials/NCT03467360
Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma
Is NCT03467360 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including acetazolamide in combination with platinum and etoposide-based radiochemotherapy and acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC for small cell lung cancer.
Treatment: acetazolamide in combination with platinum and etoposide-based radiochemotherapy · acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC — The investigators propose to study the carbonic anhydrase inhibition (acetazolamide) associated with concomitant radiochemotherapy or radioimmunotherapy in small cell lung cancer due to: 1. The over-expression of carbonic anhydrases in this type of cancer, 2. The Anti-tumor effect in preclinical acetazolamide in various tumor lines including neuroendocrine tumor lines, 3. The observed synergy between irradiation and inhibition of carbonic anhydrases, 4. Potential anti-tumor immune effect caused by decreased extracellular acidity.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage LOCALIZED, EXTENSIVE
Excluded: Stage IV
histologically non-metastatic localized (or extensive SCLC sub-group) Small cell lung cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemotherapy with platinum and etoposide (platinum, etoposide) — localized SCLC sub-group
Patient who must start radiotherapy treatment combined with chemotherapy with platinum and etoposide (localized SCLC sub-group)
Must have received: chemoimmunotherapy with platinum salts, etoposide and immunotherapy (platinum salts, etoposide, atezolizumab, durvalumab) — extensive SCLC sub-group
Patient who received 4 cycles of chemoimmunotherapy with platinum salts, etoposide and immunotherapy (atezolizumab or durvalumab) as the first treatment (extensive SCLC sub-group)
Cannot have received: thoracic irradiation
History of thoracic irradiation or near / in the thoracic irradiation field
Lab requirements
Cardiac function
congestive heart failure unbalanced (ejection fraction <30%, clinical signs)
Contraindication to thoracic radiotherapy treatment: congestive heart failure unbalanced (ejection fraction <30%, clinical signs), severe respiratory failure
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03467360 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior thoracic irradiation disqualifies patients from enrollment.
What disease stage is eligible?
Stage LOCALIZED or EXTENSIVE is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages